Prostate cancer surgical decision-making, unified and auditable
A decision-dense market, a product that integrates what is scattered today, and a revenue model spanning the individual physician to the hospital.
patients in the PRECE training cohort
validated at 2 centers
AUC of the Briganti nomogram
European multicenter validation
validated calculators and nomograms
PRECE, Briganti, Trifecta, MSKCC suite
biopsy sectors mapped in 3D
per-sector risk heatmap
The surgical treatment of prostate cancer concentrates extremely high-impact decisions — nerve-sparing, lymph node dissection, prognosis — that today rely on scattered nomograms, spreadsheets and memory. ProstPlanAI unifies these validated models, adds 3D visualization and AI-powered report extraction, and delivers the decision translated into surgical management. One workflow, auditable, across every platform.
Why we win
A single workflow, not a standalone calculator
Input → PRECE → 3D → Trifecta → Report. Competitors offer isolated nomograms; ProstPlanAI integrates 10 validated models into a single decision path.
Side-by-side decision, surgical granularity
Nerve-sparing is decided side by side — precision that generic nomograms do not offer and that directly impacts potency and continence.
Two-layer AI
Generative AI (Gemini) to extract reports and remove entry friction; auditable nomograms for the prediction. Each number comes with its method and reference — genuine explainable AI.
Multiplatform on a single backend
iOS, iPad, Android and web share the same backend (Supabase + Edge Functions), without rewriting the clinical logic or the 3D. It scales without duplicating engineering cost.
Compliance by design
LGPD consent, per-user RLS, account deletion, clinical disclaimer and auditable algorithms — ready for regulatory and institutional scrutiny.
Three-tier revenue model
Freemium (2 calculations/month, no case saving) → individual subscription (US$ 14.99/month, US$ 149.99/year — US reference, varies by country) + extraction credits → Enterprise by seats via Stripe. It covers the individual urologist and the institution.
Where we play
A specialty with high decision density
Prostate cancer is one of the most prevalent tumors in men, and each surgical case concentrates multiple quantifiable decisions — the ideal setting for decision support.
B2C entry, B2B expansion
The individual urologist adopts for the immediate value in the office; the hospital adopts for standardization and the auditable record. The same product serves both.
Native trilingual reach
Interface and plans in Portuguese, English and Spanish — ready for the largest urology markets in the Americas and Europe.
Let's talk
Full deck, traction metrics and roadmap on request. Get in touch to schedule a presentation.
contato@prostplanai.com